# Rani Therapeutics

> Rani Therapeutics is a clinical-stage biotherapeutics company building the RaniPill, a swallowable robotic capsule that delivers injectable biologics - peptides, proteins and antibodies - orally, with dissolvable microneedles that painlessly inject the drug into the intestinal wall. Founded in 2012 out of Mir Imran's InCube Labs and now Nasdaq-listed (RANI), Rani aims to replace the needle for chronic conditions ranging from obesity and metabolic disease to immunology and rare disease.

- **Founded:** 2012
- **Headquarters:** San Jose, California, United States
- **Founders:** Mir Imran (Founder & Executive Chairman)
- **Team size:** ~110 employees
- **Products:** RaniPill Capsule, RaniPill HC (High Capacity), RT-114, Oralization Platform / Partnering
- **Notable:** First-in-human study of the 'robotic' RaniPill capsule demonstrating safe delivery and high bioavailability of biologics orally, Reported ~102% bioavailability of delivered drug relative to subcutaneous injection in studies, IPO on Nasdaq (RANI) in 2021

## Products & services

- **RaniPill Capsule** — A swallowable robotic capsule that passes intact through the stomach, then in the small intestine inflates a self-deploying balloon that pushes a dissolvable, drug-filled microneedle into the highly vascularized intestinal wall - a painless 'injection from the inside' delivering peptides, proteins and antibodies with injectable-level bioavailability (reported ~102% relative to subcutaneous).
- **RaniPill HC (High Capacity)** — A higher-payload version of the platform designed to carry larger drug volumes (20 mg or more), broadening the range of biologics that can be oralized.
- **RT-114** — Lead clinical candidate: a RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist (licensed from ProGen) for the treatment of obesity. A Phase 1 study was initiated in January 2026.
- **Oralization Platform / Partnering** — Rani applies its delivery technology to partners' biologics, converting injectables into oral capsules under collaboration and licensing agreements (e.g., Chugai).

## Achievements

- First-in-human study of the 'robotic' RaniPill capsule demonstrating safe delivery and high bioavailability of biologics orally
- Reported ~102% bioavailability of delivered drug relative to subcutaneous injection in studies
- IPO on Nasdaq (RANI) in 2021
- Signed collaboration worth up to ~$1.085 billion with Chugai Pharmaceutical (2025)
- Initiated Phase 1 of RT-114 RaniPill for obesity with ProGen (January 2026)
- Extensive patent portfolio around oral biologic delivery

## Latest updates

- **2026-05** — Reported Q1 2026 results: cash of $43.4M (runway into Q4 2027), contract revenue up to $1.7M, net loss narrowed to $8.0M; announced CFO transition and new strategic advisors (Jesper Hoiland, Dr. Sara Kenkare-Mitra).
- **2026-01** — Initiated Phase 1 study of RT-114 RaniPill for obesity in collaboration with ProGen, evaluating an orally delivered GLP-1/GLP-2 dual agonist.
- **2025-10** — Announced up to $1.085B collaboration with Chugai Pharmaceutical and concurrent oversubscribed $60.3M financing.

## Links

- Website: https://ranitherapeutics.com
- LinkedIn: https://www.linkedin.com/company/rani-therapeutics-llc

---

Profile page: https://yespress.io/rani-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-20